Biotech company Praetego Inc. has raised $20,000 and wants to raise a total of $400,000, according to a Tuesday filing with the Securities and Exchange Commission.

The money came in the form of a combination debt and equity and option.

The filing was signed by CEO Pepper Landson.

Landson was previously vice president of clinical operations at NephroGenex.

The Raleigh-based company, which was founded in 2017, is developing prophylactic therapies for surgical and critical care patients.

Its lead therapy candidate is an intravenous formulation to protect against the development of acute kidney injury, following cardiac surgery.

Companies relying on a Reg D exemption do not have to register their offering of securities with the SEC, but they must file what’s known as a Form D electronically with the SEC after they first sell their securities.